+

WO2004099366A3 - Optimisation parallele sensible au contexte de domaines de liaison a l'adn en doigt de zinc - Google Patents

Optimisation parallele sensible au contexte de domaines de liaison a l'adn en doigt de zinc Download PDF

Info

Publication number
WO2004099366A3
WO2004099366A3 PCT/US2003/034010 US0334010W WO2004099366A3 WO 2004099366 A3 WO2004099366 A3 WO 2004099366A3 US 0334010 W US0334010 W US 0334010W WO 2004099366 A3 WO2004099366 A3 WO 2004099366A3
Authority
WO
WIPO (PCT)
Prior art keywords
dna binding
zinc finger
binding domains
context sensitive
finger dna
Prior art date
Application number
PCT/US2003/034010
Other languages
English (en)
Other versions
WO2004099366A2 (fr
Inventor
Keith J Joung
Carl Pabo
Original Assignee
Gen Hospital Corp
Massachussetts Inst Of Technlo
Keith J Joung
Carl Pabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Massachussetts Inst Of Technlo, Keith J Joung, Carl Pabo filed Critical Gen Hospital Corp
Priority to US10/532,258 priority Critical patent/US20070178454A1/en
Priority to AU2003304086A priority patent/AU2003304086A1/en
Publication of WO2004099366A2 publication Critical patent/WO2004099366A2/fr
Publication of WO2004099366A3 publication Critical patent/WO2004099366A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes destinées à identifier des polypeptides Zf à doigts multiples se liant à une séquence d'intérêt. Les polypeptides Zf identifiés au moyen des méthodes susmentionnées peuvent présenter une affinité et une spécificité pour leurs sites cibles supérieures par rapport à ceux produits au moyen d'autres méthodes.
PCT/US2003/034010 2002-10-21 2003-10-23 Optimisation parallele sensible au contexte de domaines de liaison a l'adn en doigt de zinc WO2004099366A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/532,258 US20070178454A1 (en) 2002-10-21 2003-10-23 Context sensitive paralell optimization of zinc finger dna binding domains
AU2003304086A AU2003304086A1 (en) 2002-10-23 2003-10-23 Context sensitive parallel optimization of zinc finger dna binding domains

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42045802P 2002-10-23 2002-10-23
US60/420,485 2002-10-23
US46688903P 2003-04-30 2003-04-30
US60/466,889 2003-04-30

Publications (2)

Publication Number Publication Date
WO2004099366A2 WO2004099366A2 (fr) 2004-11-18
WO2004099366A3 true WO2004099366A3 (fr) 2006-07-20

Family

ID=33436673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034010 WO2004099366A2 (fr) 2002-10-21 2003-10-23 Optimisation parallele sensible au contexte de domaines de liaison a l'adn en doigt de zinc

Country Status (2)

Country Link
AU (1) AU2003304086A1 (fr)
WO (1) WO2004099366A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2732038B1 (fr) 2011-07-15 2018-09-05 The General Hospital Corporation Procédés d'assemblage d'effecteurs de type activateur de la transcription
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
EP3789405A1 (fr) 2012-10-12 2021-03-10 The General Hospital Corporation Protéines de fusion effecteur de type activateur de transcription (tale) - déméthylase 1 spécifique de la lysine (lsd1)
EP2954042B1 (fr) 2013-02-07 2017-12-06 The General Hospital Corporation Activateurs transcriptionnels tale
WO2014204578A1 (fr) 2013-06-21 2014-12-24 The General Hospital Corporation Utilisation de nucléases foki à guidage arn (rfn) afin d'augmenter la spécificité pour l'édition de génome par guidage arn
EP2970986B1 (fr) 2013-03-15 2020-05-06 The General Hospital Corporation Direction, par guidage arn, de protéines régulatrices génétiques et épigénomiques vers des loci génomiques spécifiques
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
DK3066201T3 (en) 2013-11-07 2018-06-06 Editas Medicine Inc CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES
CN106604994B (zh) 2014-06-23 2021-12-14 通用医疗公司 通过测序评估的DSBs的全基因组无偏鉴定(GUIDE-Seq)
AU2015324935B2 (en) 2014-10-01 2021-04-08 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
US20180296537A1 (en) 2015-06-05 2018-10-18 Novartis Ag Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
JP2018530536A (ja) 2015-09-11 2018-10-18 ザ ジェネラル ホスピタル コーポレイション ヌクレアーゼＤＳＢの完全照合およびシーケンシング（ＦＩＮＤ−ｓｅｑ）
US9850484B2 (en) 2015-09-30 2017-12-26 The General Hospital Corporation Comprehensive in vitro reporting of cleavage events by sequencing (Circle-seq)
KR20240064734A (ko) 2016-10-14 2024-05-13 더 제너럴 하스피탈 코포레이션 후성적으로 조절되는 부위-특이적 뉴클레아제
US11326157B2 (en) 2017-05-25 2022-05-10 The General Hospital Corporation Base editors with improved precision and specificity
EP3921417A4 (fr) 2019-02-04 2022-11-09 The General Hospital Corporation Variants d'éditeur de base d'adn adénine avec édition d'arn hors cible réduite
ES2938896T3 (es) 2019-10-21 2023-04-17 Univ Freiburg Albert Ludwigs Un ensayo in vitro verdaderamente imparcial para perfilar la actividad fuera de objetivo de una o más nucleasas programables específicas de objetivo en células (ABNOBA-SEQ)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHANDRASEGARAN S.: "Chimeric Restriction Enzymes: What is Next?", BIOLOGICAL CHEMISTRY, vol. 380, 1999, pages 841 - 848, XP008019125 *
CHOCO Y. ET AL.: "In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence", NATURE, vol. 372, 15 December 1994 (1994-12-15), pages 642 - 645, XP003001072 *
HANES J. ET AL.: "Comparison of Escherichia coli and rabbit reticulocyte ribosome display systems", FEBS., vol. 450, 1999, pages 105 - 110, XP002178365 *
WOLFE S. A. ET AL.: "Combining structure-based design with phage display to create new Cy2His2 zinc finger dimers", STRUCTURE, vol. 8, 21 June 2000 (2000-06-21), pages 739 - 750, XP008070579 *

Also Published As

Publication number Publication date
WO2004099366A2 (fr) 2004-11-18
AU2003304086A8 (en) 2004-11-26
AU2003304086A1 (en) 2004-11-26

Similar Documents

Publication Publication Date Title
WO2004099366A3 (fr) Optimisation parallele sensible au contexte de domaines de liaison a l'adn en doigt de zinc
WO2004092219A3 (fr) Modification d'affinites de liaison pour fcrn ou de demi-vies de serum d'anticorps par mutagenese
EP1789447A4 (fr) Méthode d'interférence arn et utilisations
WO2005123780A3 (fr) Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
WO2004033631A8 (fr) Sequences d'acides nucleiques et polypeptidiques de lawsonia intracellularis et methodes d'utilisation
SI1562972T1 (sl) ALTERACIJA FcRn VEZANIH AFINITET ALI SERUMSKIH RAZPOLOVNIH DOB ANTITELESC Z MUTAGENEZO
EP1864998A3 (fr) Molécules de liaison
WO2001049823A3 (fr) Dosage pour la detection de bacillus anthracis
WO2004074310A8 (fr) Diagnostics de mycobactéries
SI1697421T1 (sl) Bispecifična protitelesa
BR0011849A (pt) Anticorpos enxertados lm609 melhorados
WO2008022152A3 (fr) Anticorps optimisés ciblant cd19
WO2005011376A3 (fr) Anticorps modifies presentant une affinite de liaison a l'antigene amelioree
WO2004035603A3 (fr) Anticorps se liant au recepteur de l'erythropoietine
WO2003074679A3 (fr) Optimisation d'anticorps
WO2005010049A3 (fr) Compositions de liaison et reactifs associes
EP3300739A3 (fr) Anticorps et molécules correspondantes se liant aux protéines 161p2f10b
EP1363125A3 (fr) Determination de profils des facteurs de transcription sur une surface solide
WO2003093472A3 (fr) Acides nucleiques liant le cgrp
WO2003087138A3 (fr) Procedes d'identification de facteurs polypeptidiques ayant une interaction avec l'arn
WO2006034278A3 (fr) Procedes et compositions de detection du cancer au moyen de composants de la particule spliceosomale u2
DE60031965D1 (de) Hochsensitiver nachweis von biomolekülen mittels "phage display"
WO2006033742A3 (fr) Fragment d'anticorps genetiquement modifie qui se lie a un antigene de maniere irreversible
WO2004081029A3 (fr) Nouveau marqueur non invasif des maladies du foie
WO2009045075A3 (fr) Anticorps monoclonal spécifique des cellules souches embryonnaires humaines, hybridome sécrétant ce dernier et procédé permettant de détecter ou d'isoler une cellule souche embryonnaire non différenciée

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWE Wipo information: entry into national phase

Ref document number: 10532258

Country of ref document: US

Ref document number: 2007178454

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 10532258

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载